Our latest industry analytics report features analysis on the digital sector within the life sciences industry. Clinical Professionals Divisional Manager (Commercial), Thomas Hancox comments on the findings: “The landscape of digital is changing across the world and it is well known amongst the industry’s top professionals that pharma has lacked the freedom within the digital
Patient dosing has begun in a Phase III clinical programme investigating GSK’s 5-in-1 meningitis (MenABCWY) vaccine candidate compared to licensed meningococcal vaccines, Bexsero and Menveo. Invasive Meningococcal Disease (IMD) is uncommon, with country-specific reported cases ranging from 0.1 to 2.4 cases per 100,000 population in 2017. However, the disease can kill in as few as
“You never change things by fighting the existing reality. To change something, build a new model” Our latest industry analytics report features analysis on the clinical sector within the life sciences industry. Clinical Professionals Group CEO, Yvette Cleland comments: “Covid19 has been a global disruptor in literally every section of society. However, for the future
A highly anticipated COVID-19 vaccine which is being jointly developed by AstraZeneca and Oxford University has produced encouraging results in a phase 1/2 trial. The phase 1/2 results, published in The Lancet demonstrated that the vaccine, AZD1222, produced a robust immune response against the SARS-CoV-2 virus in all participants in the study. The vaccine also proved safe to use,
The American biotech’s COVID-19 vaccine has shown promise in a key early trial by producing antibodies in all the participants tested. The interim analysis of the phase 1 study of the candidate, mRNA-1273, evaluated a two-dose vaccination schedule of the shot given 28 days apart across three dosages – 25, 100, 250 µg – in 45
Regeneron Pharmaceuticals has kickstarted a Phase III trial evaluating its double antibody cocktail for prevention of novel coronavirus infection in uninfected people who have had ‘close exposure’ to a COVID-19 patient in a Phase III trial. The experimental therapy has also advanced into the Phase II/III segment of two adaptive trials assessing its ability to
NHS and Sobi UK have come to an agreement that will give people living with haemophilia A in the UK increased access to Elocta, by lifting prior volume restrictions for the drug. Elocta is licensed by the European Commission in all age groups for treatment and prevention of bleeding in patients with haemophilia A. It
Date: Thursday, July 2nd Time: 12pm In conjunction with CPL’s Future of Work Institute and Cpl Specialist Talent, the Clinical Professionals Group invites you to our UK based Webinar Series “Perspectives on the Future of STEM”. During these times the world of work is changing for every industry, and STEM (Science, Technology, Engineering & Mathematics.) is no
Our latest industry analytics report features analysis on the procurement sector within the life sciences industry. Clinical Professionals Group CEO, Yvette Cleland comments: “As control of spend becomes more prominent in biopharmaceutical management’s message to the investor community, attention has been focused heavily again to the finance portfolio and most prominently through sourcing and procurement.
AstraZeneca will start clinical trials of two antibodies targeting SARS-CoV-2, the virus that causes COVID-19, within the next two months. The two candidates have emerged from a partnership with Vanderbilt University in the US – focusing on up to six coronavirus-targeting neutralising antibodies – which was signed in April. The antibodies have the potential to
